Analysis of the open label data from FLAMINGO-01 has commenced and has been conducted in a manner that maintains the study blind. A preliminary review of FLAMINGO-01 HLA data in both the HLA-A*02 ...
STAFFORD, Texas - Greenwich LifeSciences, Inc. (NASDAQ:GLSI), a clinical-stage biopharmaceutical company valued at $163 million, has announced the commencement of analysis on the open label HLA data ...
GlobalData on MSN12d
EMA approves addition of sites to Greenwich LifeSciences’ breast cancer trialThe European Medicines Agency (EMA) has approved the expansion of Greenwich LifeSciences’ Phase III FLAMINGO-01 breast cancer ...
Greenwich LifeSciences updates on commercial manufacturing of GP2 and prepares for BLA filing for GLSI-100 in breast cancer treatment. Greenwich LifeSciences, Inc. announced progress in the ...
In the last year, multiple insiders have substantially increased their holdings of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) stock, indicating that insiders' optimism about the company's ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase ...
Greenwich LifeSciences, Inc. announced progress in its Phase III clinical trial FLAMINGO-01, which is studying its immunotherapy GLSI-100 to prevent breast cancer recurrences. The European ...
Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie ...
Greenwich LifeSciences (GLSI) announced an update on FLAMINGO-01 open label HLA data. Analysis of the open label data from FLAMINGO-01 has ...
In the last year, multiple insiders have substantially increased their holdings of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) stock, indicating that insiders' optimism about the company's prospects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback